ESTRO 2025 - Abstract Book

S1833

Clinical – Upper GI

ESTRO 2025

Keywords: hypofractionated radiotherapy, pancreatic pancer

References: (1) Passoni P, Reni M, Broggi S, et al: Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Clin Transl Radiat Oncol 2024;47:100778. doi: 10.1016/j.ctro.2024.100778. (2) Broggi S, Passoni P, Tiberio P et al: Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy. Front Oncol 2023;12:983984. doi: 10.3389/fonc.2022.983984.

3493

Digital Poster Re-irradiation in recurrent esophageal cancer: toxicity and survival Chiara Mattioli 1 , Lucy A. van Werkhoven 2 , Joost J. Nuyttens 2 1 Radiation Oncology, Azienda Ospedaliero Universitaria Careggi, Università di Firenze, Firenze, Italy. 2 Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands Purpose/Objective: This trial aimed to assess the survival outcomes and toxicity of recurrent local esophageal cancer treated with curative (cRT) and palliative (pRT) reirradiation. Material/Methods: From May 2015 to August 2024, 41 patients with recurrent local esophageal cancer were treated with either cRT or pRT. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Overall survival (OS) was analyzed using the Kaplan-Meier method. Clinical benefit of pRT (such as reduction of dysphagia, pain or bleeding) was assessed 3-4 weeks after the final fraction. All patients were treated with Volumetric Arc Radiotherapy.